A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease

Virology Journal

Volumn 9, Issue , 2012, Pages

  Israely, Tomer ^a   Paran, Nir ^a   Lustig, Shlomo ^a   Erez, Noam ^a   Politi, Boaz ^a   Shafferman, Avigdor ^a   Melamed, Sharon ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Cidofovir; Ectromelia; Poxvirus; Single post exposure treatment; Vaccinia

Indexed keywords

CIDOFOVIR; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ANTIVIRUS AGENT; CYTOSINE; DRUG DERIVATIVE; IMMUNOGLOBULIN G; PHOSPHONIC ACID DERIVATIVE; VIRUS ANTIBODY;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIVER; LUNG; MORBIDITY; MORTALITY; MOUSE; MOUSEPOX; NONHUMAN; SINGLE DRUG DOSE; SURVIVAL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG EFFECT; ECTROMELIA VIRUS; FEMALE; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY;

ANIMALIA; ECTROMELIA VIRUS; MUS; ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOSINE; DISEASE MODELS, ANIMAL; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PHOSPHONIC ACIDS; SURVIVAL ANALYSIS;

EID: 84862245297     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-119     Document Type: Article

References (44)

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, Smallpox and its Eradication World Health Organization, Geneva, Switzerland 1988
2. WHO: World Health Organization, The global eradication of smallpox: final report of the global commission for the certrification of smallpox eradication.History of International Public Health No 4 World Health Organization, Geneva, Switzerland 1980
3. The looming threat of bioterrorism. Henderson DA, Science 1999 283 5406 1279 1282 10.1126/science.283.5406.1279 10037590 (Pubitemid 29108987)
4. Can postexposure vaccination against smallpox succeed? Mortimer PP, Clin Infect Dis 2003 36 5 622 629 10.1086/374054 12594644 (Pubitemid 36259569)
5. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Parker S, Handley L, Buller RM, Future Virol 2008 3 6 595 612 10.2217/17460794.3.6.595 19727418
6. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L, Spano YE, et al. Proc Natl Acad Sci USA 2008 105 31 10889 10894 10.1073/pnas.0804985105 18678911
7. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, et al. J Infect Dis 2009 199 1 39 48 10.1086/595565 19012492
8. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H, J Clin Invest 2008 118 5 1776 1784 10.1172/JCI33940 18398511 (Pubitemid 351632380)
9. Poxvirus pathogenesis. Buller RM, Palumbo GJ, Microbiol Rev 1991 55 1 80 122 1851533 (Pubitemid 21895147)
10. Ectromelia virus: the causative agent of mousepox. Esteban DJ, Buller RM, J Gen Virol 2005 86 Pt 10 2645 2659 16186218 (Pubitemid 41410454)
11. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. Panchanathan V, Chaudhri G, Karupiah G, J Virol 2006 80 13 6333 6338 10.1128/JVI.00115-06 16775321 (Pubitemid 43927436)
12. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R, Painter G, Robertson A, Buller RM, Virology 2009 385 1 11 21 10.1016/j.virol.2008.11.015 19100593
13. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM, Antiviral Res 2008 77 1 39 49 10.1016/j.antiviral.2007.08.003 17904231
14. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW, Antimicrob Agents Chemother 2002 46 5 1329 1335 10.1128/AAC.46.5.1329-1335.2002 11959564 (Pubitemid 34415310)
15. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. Wei H, Huang D, Fortman J, Wang R, Shao L, Chen ZW, J Virol 2009 83 2 1115 1125 10.1128/JVI.00984-08 19004937
16. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy. Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RM, Virology 2011 409 2 328 337 10.1016/j.virol.2010.10.021 21071055
17. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, Bolken TC, Hruby DE, Proc Natl Acad Sci USA 2010 107 2 838 843 10.1073/pnas.0912134107 20080762
18. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Snoeck R, De Clercq E, Curr Opin Investig Drugs 2002 3 11 1561 1566 12476953 (Pubitemid 36266727)
19. Antiviral prophylaxis of smallpox. Bray M, Roy CJ, J Antimicrob Chemother 2004 54 1 1 5 10.1093/jac/dkh286 15163655 (Pubitemid 39028959)
20. In vivo imaging of cidofovir treatment of cowpox virus infection. Goff A, Twenhafel N, Garrison A, Mucker E, Lawler J, Paragas J, Virus Res 2007 128 1-2 88 98 17524511 (Pubitemid 47243618)
21. Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection. Knorr CW, Allen SD, Torres AR, Smee DF, Antiviral Res 2006 72 2 125 133 10.1016/j.antiviral.2006.05.005 16782209 (Pubitemid 44332568)
22. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Neyts J, Leyssen P, Verbeken E, De Clercq E, Antimicrob Agents Chemother 2004 48 6 2267 2273 10.1128/AAC.48.6.2267-2273.2004 15155231 (Pubitemid 38691628)
23. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holy A, De Clercq E, Niesters HG, Fries E, Maas C, et al. Nature 2006 439 7077 745 748 10.1038/nature04295 16341204 (Pubitemid 43237623)
24. mallpox vaccination and adverse reactions. Guidance for clinicians. Cono JCCG, Bell DM, CDC NMWR Recommendations and Reports 2003
25. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY, Virology 2004 318 2 474 481 10.1016/j.virol.2003.11.015 14972516 (Pubitemid 38224291)
26. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Dropulic LK, Cohen JI, Clin Pharmacol Ther 2010 88 5 610 619 10.1038/clpt.2010.178 20881959
27. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY, Antimicrob Agents Chemother 2002 46 4 991 995 10.1128/AAC.46.4.991-995.2002 11897580 (Pubitemid 34260341)
28. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Quenelle DC, Collins DJ, Herrod BP, Keith KA, Trahan J, Beadle JR, Hostetler KY, Kern ER, Antimicrob Agents Chemother 2007 51 11 3940 3947 10.1128/AAC.00184-07 17846137 (Pubitemid 350057792)
29. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S, J Virol 2010 84 8 3909 3920 10.1128/JVI.02012-09 20130052
30. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER, Antimicrob Agents Chemother 2007 51 11 4118 4124 10.1128/AAC.00762-07 17724153 (Pubitemid 350057813)
31. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R, Antiviral Res 2008 79 2 121 127 10.1016/j.antiviral.2008.03.005 18479761
32. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, et al. J Virol 2005 79 20 13139 13149 10.1128/JVI.79.20.13139-13149.2005 16189015 (Pubitemid 41433232)
33. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW, J Infect Dis 2000 181 1 10 19 10.1086/315190 10608745 (Pubitemid 30049027)
34. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM, Antivir Ther 2008 13 7 863 873 19043920
35. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Quenelle DC, Collins DJ, Kern ER, Antimicrob Agents Chemother 2003 47 10 3275 3280 10.1128/AAC.47.10.3275-3280.2003 14506041 (Pubitemid 37229589)
36. Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Quenelle DC, Kern ER, Viruses 2010 2 12 2681 2695 10.3390/v2122681 21994637
37. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Smee DF, Bailey KW, Wong MH, Sidwell RW, Antiviral Res 2001 52 1 55 62 10.1016/S0166-3542(01)00159-0 11530188 (Pubitemid 32800691)
38. Dose translation from animal to human studies revisited. Reagan-Shaw S, Nihal M, Ahmad N, FASEB J 2008 22 3 659 661 17942826 (Pubitemid 351348146)
39. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Cundy KC, Clin Pharmacokinet 1999 36 2 127 143 10.2165/00003088-199936020-00004 10092959 (Pubitemid 29121686)
40. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. Neyts J, De Clercq E, J Med Virol 1993 41 3 242 246 10.1002/jmv.1890410312 8263505 (Pubitemid 23327056)
41. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances. Smee DF, Bailey KW, Wong MH, Tarbet EB, Antivir Chem Chemother 2011 21 5 201 208 10.3851/IMP1734 21566266
42. Ring vaccination and smallpox control. Kretzschmar M, van den Hof S, Wallinga J, van Wijngaarden J, Emerg Infect Dis 2004 10 5 832 841 10.3201/eid1005.030419 15200816 (Pubitemid 38552750)
43. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B, J Virol 2005 79 21 13454 13462 10.1128/JVI.79.21.13454- 13462.2005 16227266 (Pubitemid 41508158)
44. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Melamed S, Paran N, Katz L, Ben-Nathan D, Israely T, Schneider P, Levin R, Lustig S, Vaccine 2007 25 45 7743 7753 10.1016/j.vaccine.2007.09.023 17928110 (Pubitemid 47588531)